{"name":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","slug":"grupo-espanol-de-trabajo-en-enfermedad-de-crohn-y-colitis-ulcerosa","ticker":"","exchange":"","domain":"","description":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) is a Spanish organization focused on research and treatment of Crohn's disease and ulcerative colitis. The group collaborates with healthcare professionals to improve patient outcomes and advance the understanding of inflammatory bowel diseases.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Discontinuation of thiopurines.","genericName":"Discontinuation of thiopurines.","slug":"discontinuation-of-thiopurines","indication":"Crohn's disease maintenance therapy de-escalation","status":"marketed"}]}],"pipeline":[{"name":"Discontinuation of thiopurines.","genericName":"Discontinuation of thiopurines.","slug":"discontinuation-of-thiopurines","phase":"marketed","mechanism":"Discontinuation of thiopurines involves stopping the use of immunosuppressive purine analogs to assess disease control and reduce long-term toxicity risks.","indications":["Crohn's disease maintenance therapy de-escalation","Ulcerative colitis maintenance therapy de-escalation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZ05ndHN4cGFPV01ESHZGeFhVSjBPbWdVbU5FRmlfajU3ZGp3aFFtZml3VUl5aEZjbmpSamxZM1FqQmxSM3ZNdHpXVFRaenhtTHI2b1Q0YXlmVWEtLWxJVDk1a0JjVHB2Y3RJSGx3X2daQ0FzX1BQQmhoSUpJZ1JOekI3RmtMQ1M3?oc=5","date":"2021-04-15","type":"pipeline","source":"SciELO España","summary":"Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease - SciELO España","headline":"Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease - ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}